Stock Groups

AstraZeneca seeks U.S. authorisation of drug to prevent COVID-19 By Reuters

by Mike Robinson

[ad_1]

© Reuters. FILEPHOTO: AstraZeneca’s logo can be seen outside of its North America headquarters at Wilmington, Delaware (U.S.A), March 22nd 2021. REUTERS/Rachel Wisniewski

(Reuters] -AstraZeneca asked the U.S. Food and Drug Administration for an emergency authorization to allow its new COVID-19 prevention treatment. The British drugmaker stated Tuesday.

Company has provided data from the late-stage clinical trial with over 5,000 participants, which showed that COVID-19 symptoms were reduced by 77%.

AstraZeneca, NASDAQ:, stated that the treatment is an antibody therapy, called AZD7442. It could be used to protect those who might not be able to produce a sufficient immune response against COVID-19 vaccinations.

AZD7442 is a vaccine that relies on the active immune system for the development of an arsenal of specific antibodies and infection-fighting cell lines. However, AZD7442 uses lab-made antibodies to linger within the body for several months in order to stop the spread of the virus.

A U.S. approval for AZD7442 may be a big win for AstraZeneca. This widely used COVID-19 vaccination has not yet been approved in the United States.

AstraZeneca reported that discussions regarding supply agreements are ongoing between the United States of America and other governments.

Disclaimer Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses that you may incur due to the use of these data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information, including buy/sell signal data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



[ad_2]